AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06494059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Intermittent theta burst stimulation (iTBS)
Description: Subjects will be fitted with a magnetic coil that is placed on top of the head that does not deliver any stimulation to the brain. Each subject is expected to participate longitudinally at least 9 times over 2 months.Each visit will take approximately 2-3 hours.
Study NCT05981573 — intervention group
Intervention type: DEVICE
Intervention: ISF extraction device 1
Description: FDA approved microneedle attached to blotter paper tested for ability to extract 1ul of interstitial fluid
Study NCT05981573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo
Description: Measurement of Methadone and its metabolites in interstitial fluid with Liquid Chromatography - Mass Spectroscopy (LC-MS) and Electrochemical Assay
Study NCT05981573 — intervention group
Intervention type: DEVICE
Intervention: Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo
Description: Measurement of Methadone and its metabolites in ISF with LC-MS and DPV
Study NCT05981573 — intervention group
Intervention type: DRUG
Intervention: Measurement of Methadone in ISF before and after taking prescribed dose
Description: Measurement of methadone in ISF using DPV ex vivo versus in vivo . (Accuracy comparison - sensitivity, specificity, level of detection, and standard deviations )
Study NCT04963504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rest-to-exercise
Description: Pulmonary diffusing capacity is assessed at rest and during exercise (70% of VO2max on a bicycle ergometer)
Study NCT04963504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sitting-to-supine
Description: Pulmonary diffusing capacity is assessed in the sitting and supine position
Study NCT05981573 — intervention group
Intervention type: DEVICE
Intervention: ISF Extraction Device 2
Description: Up to 15 minute periods of continuous ISF collection for analysis
Study NCT05649787 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised aerobic training
Description: Supervised moderate to high-intensity interval aerobic training
Study NCT05649787 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised aerobic plus low to moderate-intensity strength training
Description: Supervised moderate to high-intensity interval aerobic training plus low to moderate-intensity strength training
Study NCT05649787 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised aerobic plus moderate to high-intensity strength training
Description: Supervised moderate to high-intensity interval aerobic training plus moderate to high-intensity strength training
Study NCT06599658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (IIV) at baseline
Description: National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age at baseline
Study NCT06599658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccines at a 3-month interval
Description: Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 3-month interval
Study NCT06599658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine at Month 1
Description: National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age 1-month following initial COVID-19 booster
Study NCT06599658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccines at a 6-month interval
Description: Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 6-month interval
Study NCT04907994 — intervention group
Intervention type: OTHER
Intervention: Cohort
Description: Nothing. Only implementation of a cohort with data collection via the SNDS.
Study NCT06653400 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: paracervical block
Description: paracervical block with office hysteroscopy
Study NCT06653400 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paracervical block
Description: paracervical block with office hysteroscopy
Study NCT05448001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 20mg
Description: JP-1366 20 mg 1 capsule, Lansoprazole 30 mg placebo 1 capsule before meal
Study NCT06653400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Dosage: 20 mL of 1% lidocaine
Study NCT06653400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Dosage: 20 mL of 1% lidocaine
Study NCT06653400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac
Description: Dosage: 2 mL (30 mg) of ketorolac
Study NCT06652425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low temperature (16°C) group
Description: The exposure group will be exposed to low temperature (16°C) in a chamber for about 2 hours, resting during the whole periods.
Study NCT05448001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole 30mg
Description: JP-1366 20 mg placebo 1 capsule, Lansoprazole 30 mg 1 capsule before meal
Study NCT06652425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate temperature (22°C) group
Description: The exposure group will be exposed to thermoneutral temperature (22°C) in a chamber for about 2 hours, resting during the whole periods.
Study NCT06652776 — intervention group
Intervention type: OTHER
Intervention: Pharmacological treatment
Description: Pharmacological and non pharmacological treatments will be assessed and monitored during the retrospective and prospective phase, and will include:~* bronchodilators, inhaled steroids and their combinations~* mucolytics~* biologic therapies for COPD~* roflumilast~* pulmonary rehabilitation
Study NCT06652776 — intervention group
Intervention type: OTHER
Intervention: Pharmacological treatment
Description: All pharmacological and non pharmacological treatments for COPD will be assessed and monitored during the retrospective and prospective phase of the study, and will include:~* inhaled bronchodilators (long term beta-2 agonists and cholinergic antagonists), inhaled corticosteroids and their combinations~* mucolytics~* biologics for COPD (monoclonal antibodies)~* roflumilast~* chronic oral azythromicin~* pulmonary rehabilitation~* oxygen therapy~* non invasive/invasive ventilation
Study NCT06466395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO
Study NCT06466395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyper-CVAD
Description: Given by IV
Study NCT06573892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: Patients will receive the product twice a day, a single dose of the product is packaged in sachets. The product can be hired in the form of a powder or diluted with a small amount of water. The general course is 90 days.
Study NCT06573892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Patients will receive the product twice a day, a single dose of the product is packaged in sachets. The product can be hired in the form of a powder or diluted with a small amount of water. The general course is 90 days.
Study NCT06573892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive the product twice a day, a single dose of the product is packaged in sachets. The product can be hired in the form of a powder or diluted with a small amount of water. The general course is 90 days.
Study NCT06573892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients will receive the product twice a day, a single dose of the product is packaged in sachets. The product can be hired in the form of a powder or diluted with a small amount of water. The general course is 90 days.
Study NCT06653712 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: The following clinical data sources are used:~* Personal interview (anamnesis)~* Physical examination~* Questionnaires~* Functional assessment~* Imaging techniques~The following biological materials are used:~• Max. 30 ml of blood
Study NCT06650397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofortified maize
Description: Maize that has been grown to have higher amounts of iron and zinc.
Study NCT04730271 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Replacement
Description: Subjects will be implanted with an ATTUNE Primary total knee replacement.
Study NCT04730271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Knee Replacement
Description: Subjects will be implanted with an ATTUNE Primary total knee replacement.
Study NCT05449756 — intervention group
Intervention type: OTHER
Intervention: Self-administered questionnaires
Description: Three-monthly self-administered digital questionnaires (accessed on smartphone, tablet or computer)
Study NCT06650397 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Traditional maize
Study NCT05782140 — intervention group
Intervention type: DEVICE
Intervention: Mayo Clinic Watch Device
Description: Mayo Clinic remote monitoring platform (Omni) that utilizes a wearable device with integrated physiological monitoring capabilities.
Study NCT04481399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Strengthening Intervention for Early Childhood Development
Description: The Family Strengthening Intervention for Early Childhood Development (FSI-ECD) is an evidence-based home-visiting behavioral intervention for vulnerable families with children aged 6-36 months. The FSI-ECD targets improving parental emotion regulation and parent-child interactions to improve parental mental health and child development outcomes and reduce family violence. FSI-ECD compromises five core components delivered in 12 modules delivered in weekly sessions via active coaching by community health workers. Core components include coaching on: a) nutrition, health and hygiene; b) early stimulation and playful parenting; c) building resilience and coping skills; d) building problem-solving skills; and d) building emotion regulation and conflict resolution skills.
Study NCT04481399 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Community Health Worker Routine
Description: Standard CHW care involves three home visiting sessions delivered to families following childbirth with weekly supervision via phone or face-to-face. Topics of home visiting sessions include: skilled post-natal care for mothers, early initiation of breastfeeding and exclusive breastfeeding practices, adequate nutrition, immunization services and timely use of these services, hand washing and hygiene practices (including waste disposal and food hygiene), building the capacity of family members to appropriately take care of newborns and children under age 5, and building the capacity of family members to recognize and act on postnatal danger signs for newborns, mothers, and children under 5. CHWs also conduct screenings for acute malnutrition and growth monitoring to identify early referrals, and they can provide family planning methods, deworming tablets and other vitamins for acute malnutrition, dehydration, and anti-malaria treatment. Each home-visiting session lasts about 60 minutes.
Study NCT04929834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrating emollient + body lotion for immunotherapy-related side effects
Description: Hydrating, hypo-allergenic, and anti- itching emollient and body lotion for immunotherapy-related skin reactions
Study NCT05922540 — intervention group
Intervention type: OTHER
Intervention: Intravenous thrombolysis
Description: Intravenous thrombolysis with alteplase within the time window of stroke onset in stroke patients
Study NCT05190562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate 110 MG (Zinc 25 MG) Oral Tablet
Description: Zinc sulfate is an inorganic compound. It is used as a dietary supplement to treat zinc deficiency and to prevent the condition in those at high risk
Study NCT04682977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPROACTIF (Integrated PRimary Care and Occupational Therapy for Aging and Chronic Disease Treatment to preserve Independence and Functioning)
Description: IPROACTIF (Integrated PRimary Care and Occupational Therapy for Aging and Chronic Disease Treatment to preserve Independence and Functioning) is an intervention designed to be delivered in primary care settings by an on-site occupational therapist. Based on the premise of preventing the physical and cognitive decline that is associated with aging and chronic disease, the 12-week intervention includes a comprehensive assessment of ADL functioning and ten intervention sessions addressing disease management, physical activity and executive functioning.
Study NCT04682977 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual primary care services
Description: Usual primary care services might include monitoring of vitals and other relevant laboratory testing, prescription of medications for chronic disease management, as well as counseling for lifestyle changes.
Study NCT06290609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile Coordinated Reset
Description: The experimental device, the Stanford CR Glove, is designed to deliver vibratory stimulation to the fingertips of each hand according to a specific pattern, known as vibrotactile Coordinated Reset, which theoretically disrupts abnormal neuronal synchrony and is expected to restore function.
Study NCT04356196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina
Study NCT04356196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.
Study NCT04356196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo oral tablet
Study NCT06061601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton stroke group
Description: The exoskeleton stroke group will receive gait rehabilitation with the TWIN-Acta exoskeleton
Study NCT05935826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Essential Amino Acid Supplement by Amino Co
Description: 2 months of twice daily consumption of Purity (EAA), followed by 10 months open label extension of EAA
Study NCT05935826 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 months of twice daily consumption of Placebo, followed by 10 months open label extension of EAA
Study NCT05991141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apnea
Description: In both experimental and control groups participants walked on a treadmill at 5.5 km/h with 5º inclination for 6 minutes. The experimental group (EG) added throughout the 6 minutes intervention the following breathing pattern cyclically: 5 seconds breathing normally followed by 10 seconds of low volume apnoea, performing a total of 24 cycles of normal breathing continued by apnoea.
Study NCT05991141 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Intervention
Description: In both experimental and control groups participants walked on a treadmill at 5.5 km/h with 5º inclination for 6 minutes. The Control group (CG) performed this protocol breathing normally.
Study NCT05508633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alverine Citrate
Description: Low-dose group: Alverine (60 mg, 1 capsule) High-dose group: Alverine (120 mg, 2 capsules) The drug is orally given with 200 ml warm water after measurement of the baseline portal pressure.
Study NCT05600218 — intervention group
Intervention type: DRUG
Intervention: No intervention - Observational study
Description: Real life drug evaluation
Study NCT04239534 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Convergence Of Epicardial And Endocardial RF Ablation
Description: The epicardial lesion pattern will be created using the EPi-Sense®-AF Guided Coagulation System with VisiTrax®. Epicardial linear lesions will be created endoscopically using the EPi-Sense-AF Guided Coagulation System with VisiTrax throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. An endocardial ablation catheter will be used to ablate endocardially to connect lesions at the reflections, complete the isolation of the pulmonary veins and create a cavotricuspid lesion to prevent typical atrial flutter. Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi- Sense-AF Guided Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation.
Study NCT06331052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-guided Focused Ultrasound Ablation
Description: 3-D tractography Vim-FUSA -D tractography Vim-FUSA will be carried out as follows: (a) head shaving and placement of the stereotactic frame (Integra radionics frame, Integra Lifesciences, NJ, USA) secured to the skull with transcutaneous screws; (b) positioning on the procedure table and placement of the ultrasound transducer; (c) acquisition of conventional magnetic resonance (MR) imaging and co-registration with the CT head and 3-D tractography imaging acquired pre-surgically; (d) exploration of the target area with subtherapeutic sonications; (e) intraoperative monitoring with clinical testing of tremor and side effects with a standardized protocol. (f) Therapeutic sonications in the target area to deliver definitive ablation followed by clinical testing of tremor and side effects with a standardized protocol as described in section (e).
Study NCT05340686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Physical Exercise
Description: Moderate to vigorous physical exercise 30-45 minutes in a group setting led by psychiatric staff, 3 times per week for 6 weeks
Study NCT05340686 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxing Physical Exercise
Description: Relaxing exercises (stretching, light yoga) 30-45 minutes in a group setting led by psychiatric staff, 3 times per week for 6 weeks
Study NCT05340686 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information about physical exercise
Description: Written and oral information about physical exercise recommendations, on one occasion, by researcher
Study NCT05458479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: All participants in the study will receive open-label treatment with orally administered fluoxetine for the full duration of the 16-week trial. Fluoxetine is a selective serotonin reuptake inhibitor. It is approved for the management of major depressive disorder in adults.
Study NCT05663398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)
Description: Oral, a nonsteroidal anti-inflammatory drug
Study NCT05663398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)
Description: Oral, a nonsteroidal anti-inflammatory drug
Study NCT05394337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by vein (IV)
Study NCT05394337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Given by vein (IV)
Study NCT05102994 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: mutation test
Description: detect the tumor-related mutation in introcular fluid
Study NCT05507671 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG (Bacillus Calmette-Guérin) vaccine
Description: Application of BCG vaccine (0.1 ml intradermal) in the right arm deltoid insertion
Study NCT05236790 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Detection and classification and size measurement of polyp by Artificial Intelligence (Cad eye) and the Scale Eye
Description: Detection and classification and size measurement of polyp by Artificial Intelligence (CADeye) and Scale Eye This study will be conducted in multiple phases: phase 1 (pilot phase, n=40 polyps, about 60 patients) to evaluate the feasibility of applying Scale Eye in real-time practice, training endoscopists to work with CADe and CADx and determining the sample size and reference standard to evaluate SCALE-EYE during the second phase of the study (randomized controlled trial), phase 2 will evaluate the performance of SCALE-EYE and CAD-eye in real-time practice. The sample size for phase 2 (RCT comparing visual with scasle eye) will be based on the pilot data allowing to compare relative accuracy of size measurement with scale eye versus visual size estimation. After completion of phase 2 later phases will use instruments such as snare and/or forceps as reference measurement devices compared to relative accuracy of measurement when using scale eye.
Study NCT05383170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyPep-1
Description: Intratumoral injection
Study NCT05383170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG/ML [KEYTRUDA®]
Description: IV infusion
Study NCT04979728 — intervention group
Intervention type: OTHER
Intervention: At Home Self-Collections
Description: Directly observed at home self-collection of blood samples
Study NCT05701800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1468
Description: Sterile liquid dispersion for injection
Study NCT05507671 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of BCG solvent (0.1 ml intradermal) in the right arm deltoid insertion